Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to evaluate the long-term safety and tolerability of brexpiprazole in children and adolescent participants, aged 5 to 17, with irritability associated with autism spectrum disorder.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT04258839
Study type Interventional
Source Otsuka Pharmaceutical Development & Commercialization, Inc.
Contact
Status Completed
Phase Phase 3
Start date January 23, 2020
Completion date March 16, 2023

See also
  Status Clinical Trial Phase
Recruiting NCT05555615 - Extension Study of Pimavanserin in Irritability Associated With Autism Spectrum Disorder Phase 2/Phase 3
Terminated NCT05733390 - A Study of JZP541 in Adults With Irritability Associated With Autism Spectrum Disorder Phase 2
Recruiting NCT05523895 - Pimavanserin for the Treatment of Irritability Associated With Autism Spectrum Disorder Phase 2/Phase 3